Cite
HARVARD Citation
Köhler, W. et al. (2023). Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial. Lancet neurology. 22 (2), pp. 127-136. [Online].